Toronto, Ontario – May 26, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it will present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015 at the Grand Hyatt Hotel in New York City. The Company’s presentation by Roger Dumoulin-White, President & CEO is scheduled to begin at 1:30 pm ET and will be available via live webcast. To access the webcast, please visit http://wsw.com/webcast/marcum3/tltff About the Marcum MicroCap Conference The Marcum MicroCap Conference is dedicated to providing a forum where publicly traded companies under $500 million in market capitalization can network with the investment community. The conference features presentations by CEOs and CFOs from six principal industry sectors and provides investors with the opportunity to meet with management of these companies on a one-on-one basis. Industry … Read More

Toronto, Ontario – May 14, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, has discovered that its lead anti-cancer drug, TLD-1433, emits a fluorescent signature when light activated in a Non-Muscle Invasive Bladder Cancer (“NMIBC”) animal model. The advantages of this discovery are three fold: It can be used as a diagnostic tool for the oncologist to detect the presence of cancer cells and micro-metastases too small to be seen by the human eye. It can be used to determine sufficient uptake of TLD-1433 into the cancer cells After light activation, it can determine if the cancer cells that have absorbed the drug have been destroyed. Theralase intends to use this new discovery in the treatment of NMIBC. Clinical Treatment Protocol of NMBIC with Photo Dynamic Therapy: Intravesical installation of TLD-1433 … Read More

Toronto, Ontario – May 12, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has successfully manufactured its lead, light-activated, anti-cancer drug, TLD-1433, specifically developed for the treatment of cancer, to high purity levels. Drugs intended for in human clinical applications, such as TLD-1433, must be manufactured in accordance with Good Manufacturing Practices (“GMP”) standards. To achieve GMP standards, the normal manufacturing process involves “scaling-up” the production from small quantities to successively larger quantities to optimize the purity and yield of the drug to arrive at a commercial grade product, suitable for human applications. In April 2015, Theralase announced the completion of the manufacture of its lead anti-cancer drug in pre-commercial quantities. The Company has now completed another critical step, optimization of the manufacturing process to produce high … Read More

Toronto, Ontario – May 1, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT: TSXV) (TLTFF: OTC Pink®) released its 2014 financial results today, demonstrating an increase of 15% year over year in revenue. In 2014 and early 2015, Theralase has made dramatic strides in both its Therapeutic Laser Therapy (“TLT”) and Photo Dynamic Therapy (“PDT”) anti-cancer divisions. In the TLT division, Theralase has completed the design and initial manufacture of its next generation TLC-2000 therapeutic laser technology and is currently awaiting final Health Canada approval to launch in Canada. The TLC-2000 with patented Cell SensingTM technology is able to determine the precise location of injured tissue in a patient based upon their physical characteristics and automatically deliver an optimal dose of healing laser light energy safely and effectively to heal the damaged tissue faster and more effectively than any other laser system on the market. In the PDT division, … Read More

Toronto, Ontario – April 9, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has successfully manufactured the first pre-commercial batch of its lead anti-cancer Photo Dynamic Compound (“PDC”), TLD-1433, one of a new generation of unique light-activated anti-cancer compounds, specifically developed for the treatment of cancer. Drugs intended for in human clinical applications, such as TLD-1433, must be manufactured in accordance with Good Manufacturing Practices (“GMP”) standards. To achieve GMP standards, the normal process is a “scale-up” in production from a small quantity to validate the manufacturing process to larger pre-commercial quantities demonstrating manufacturing optimization and finally commercial quantities, produced under strict GMP standards, suitable for human use. Theralase has now successfully completed a major milestone in its anti-cancer program by having TLD-1433 successfully manufactured to pre-commercial quantities, allowing this quantity to be used in toxicology analyses, a key requirement for Health … Read More

Toronto, Ontario – April 2, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it recently held a pre “Clinical Trial Application” (“CTA”) consultation meeting with Health Canada (“HC”) with the objective of presenting its Photo Dynamic Therapy (“PDT”) technology in the treatment of cancer and seeking clinical trial design guidance. According to Health Canada, a clinical trial is defined as, “An investigation in respect of a drug, for use in humans, that involves human subjects, and that is intended to discover or verify the clinical, pharmacological or pharmacodynamic effects of the drug, identify any adverse events in respect of the drug, study the absorption, distribution, metabolism and excretion of the drug, or ascertain the safety or efficacy of the drug.” Roger Dumoulin-White, President and CEO presented Theralase’s corporate vision, preclinical data and Phase Ib clinical trial design for the Company’s lead Photo Dynamic … Read More

Toronto, Ontario – March 23, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has partnered with CiToxLAB Safety and Health Research Laboratories (“CiToxLAB”) to provide toxicology and safety pharmacology for the lead anti-cancer Photo Dynamic Compound (“PDC”), TLD-1433. In order to further identify the safe dosing range of TLD-1433 to be used in human clinical trials for Non Muscle Invasive Bladder Cancer (“NMIBC”) planned for later this year, CitoxLAB will study the effects that TLD-1433 has on biological systems, alone and when light activated and analyze any interactions that these effects may have on the functioning of normal biological processes. Theralase is currently in development of a platform of anti-cancer Photo Dynamic Therapy (“PDT”) technologies for the destruction of numerous cancers, commencing with the destruction of NMIBC. Dr. Arkady Mandel, Chief Scientific Officer stated that, “I am pleased that we have partnered … Read More

Toronto, Ontario – March 11, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today confirmation of its strategic initiatives for 2015. On March 3, 2015, Theralase closed a prospectus financing, where the Company raised $CAN 8 million from US institutional and Canadian institutional and retail investors. Completed at a 20% discount to market, these funds are considered strategic to the Company as it has now solidified relationships with influential Canadian and US institutional investors that will prove to be invaluable down the road, as the Company executes on its strategic initiatives. Theralase is now fully funded to commence and complete its two core strategic initiatives in 2015. The first core strategic initiative for the Company is the launch of the next generation TLC-2000 “Cell Sensing” therapeutic laser system in Canada in April 2015 and in the US and Europe in 3Q2015. This technology will revolutionize … Read More

Toronto, Ontario – March 3, 2015, Theralase Technologies Inc. (“Theralase” or the “Corporation”) (TSXV:TLT) (OTC Pink®: TLTFF) is pleased to announce that it has closed its previously announced public offering  (the “Offering”) of units (each, a “Unit”).  On closing, the Corporation issued an aggregate of 18,181,817 Units at a price of $0.44 per Unit for aggregate gross proceeds of approximately $8,000,000.   Each Unit consists of one common share of the Corporation (each, a “Common Share”) and one common share purchase warrant (each, a “Warrant”). Each Warrant entitles the holder to acquire an additional Common Share at a price of $0.54 for a period of 60 months following the date of issuance. Euro Pacific Canada Inc. (the “Agent”) acted as agent in connection with the Offering pursuant to the terms and conditions of an agency agreement between the Corporation and the Agent dated February 25, 2015, as amended on March 3, 2015. Ladenburg … Read More

Toronto, Ontario – February 23, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has identified a potential mechanism of how its lead anti-cancer drug works to destroy cancer cells and has also discovered a new application of the lead drug that may lead to the ability to detect the presence of cancer cells. Theralase’s lead Photo Dynamic Compound (“PDC”) TLD-1433, when combined with transferrin (a naturally occurring iron-binding blood plasma glycoprotein found in our body), was recently described in the provisional US patent application, entitled, “Transferrin Enhanced Photo Dynamic Therapy (“PDT”) Cancer Destruction”. Theralase’s Ruthenium based PDC TLD-1433 combined with transferrin has now been branded and trademarked by the Company, as RutherrinTM. RutherrinTM has demonstrated an ability to significantly increase the targeting of bladder cancer cells and in the process, significantly increase the efficacy and safety of the treatment procedure. TLD-1433 is able to bind … Read More